NRIX
Nurix Therapeutics Inc
NASDAQ · Biotechnology
$16.85
+0.90 (+5.64%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 99.65M | 76.93M | 252.81M | 234.23M | 200.40M |
| Net Income | -313,815,175 | -218,028,143 | -27,375,633 | -24,379,697 | -25,365,756 |
| EPS | — | — | — | — | — |
| Profit Margin | -314.9% | -299.2% | -10.8% | -10.4% | -12.7% |
| Rev Growth | +29.5% | +29.5% | -6.6% | +16.3% | -7.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 735.19M | 737.03M | 760.17M |
| Total Equity | — | — | 1.05B | 1.16B | 1.03B |
| D/E Ratio | — | — | 0.70 | 0.64 | 0.74 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -328,614,285 | -240,993,956 | -31,905,294 | -31,389,191 | -26,544,777 |
| Free Cash Flow | — | — | -23,615,781 | -25,443,977 | -21,239,062 |